
Opinion|Videos|October 11, 2024
Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches
Key Takeaways
- Drug interactions, patient characteristics, and steroid use are critical in LN management, influencing treatment choices and outcomes.
- Nephrologists focus on renal preservation, while rheumatologists emphasize controlling systemic lupus erythematosus, leading to differing treatment approaches.
Panelists discuss the considerations guiding treatment choices for lupus nephritis, such as drug interactions, patient characteristics, and steroid use, and how treatment approaches might differ between nephrologists and rheumatologists.
Advertisement
Episodes in this series

What considerations (eg, drug interactions, individual patient characteristics, steroid use) guide your treatment choices for managing lupus nephritis (LN)?
- How might treatment approaches for LN differ between nephrologists and rheumatologists?
Advertisement
Related to this article

Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.

Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.

A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.

After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

A case report describes the first KRAS::ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when disease relapsed as AML after transplant.

Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5


